Joan-Carles Arce1, Anders Nyboe Andersen2, Manuel Fernández-Sánchez3, Hana Visnova4, Ernesto Bosch5, Juan Antonio García-Velasco6, Pedro Barri7, Petra de Sutter8, Bjarke M Klein9, Bart C J M Fauser10. 1. Reproductive Health, Ferring Pharmaceuticals, Copenhagen, Denmark. Electronic address: jca@ferring.com. 2. Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 3. IVI Sevilla, Seville, Spain. 4. IVF CUBE SE, Prague, Czech Republic. 5. IVI Valencia, Valencia, Spain. 6. IVI Madrid, Madrid, Spain. 7. Obstetrics, Gynecology & Reproduction, IU Dexeus, Barcelona, Spain. 8. Reproductive Medicine, Universitair Ziekenhuis, Ghent, Belgium. 9. Global Biometrics, Ferring Pharmaceuticals, Copenhagen, Denmark. 10. Division Woman & Baby, University Medical Center Utrecht, Utrecht, the Netherlands.
Abstract
OBJECTIVE: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antimüllerian hormone (AMH) concentrations. DESIGN: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial. SETTING:Seven infertility centers in four countries. PATIENT(S): Two hundred sixty-five women aged ≤37 years. INTERVENTION(S): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle. MAIN OUTCOME MEASURE(S): Number of oocytes retrieved. RESULT(S): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10% increase in dose resulted in 0.5 (95% confidence interval 0.2-0.7) and 1.0 (95% confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum. CONCLUSION(S): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level. CLINICAL TRIAL REGISTRATION NUMBER: NCT01426386.
RCT Entities:
OBJECTIVE: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antimüllerian hormone (AMH) concentrations. DESIGN: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial. SETTING: Seven infertility centers in four countries. PATIENT(S): Two hundred sixty-five women aged ≤37 years. INTERVENTION(S): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle. MAIN OUTCOME MEASURE(S): Number of oocytes retrieved. RESULT(S): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10% increase in dose resulted in 0.5 (95% confidence interval 0.2-0.7) and 1.0 (95% confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum. CONCLUSION(S): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level. CLINICAL TRIAL REGISTRATION NUMBER: NCT01426386.
Authors: AbdelGany M A Hassan; Mohamed M M Kotb; Ahmed M A AwadAllah; Nesreen A A Shehata; Amr Wahba Journal: J Assist Reprod Genet Date: 2017-07-03 Impact factor: 3.412
Authors: Jared C Robins; Andrew F Khair; Eric A Widra; Michael M Alper; Winnie W Nelson; Eric D Foster; Anshul Sinha; Masakazu Ando; Patrick W Heiser; Gaurang S Daftary Journal: F S Rep Date: 2020-11-10
Authors: Sarah F Lensen; Jack Wilkinson; Jori A Leijdekkers; Antonio La Marca; Ben Willem J Mol; Jane Marjoribanks; Helen Torrance; Frank J Broekmans Journal: Cochrane Database Syst Rev Date: 2018-02-01
Authors: Olga Haakman; Tina Liang; Kristen Murray; Angelos Vilos; George Vilos; Carlee Bates; Andrew J Watson; Michael R Miller; Basim Abu-Rafea Journal: F S Rep Date: 2020-12-14